Last reviewed · How we verify
intravitreal ranibizumab injections
intravitreal ranibizumab injections is a VEGF inhibitor (monoclonal antibody fragment) Small molecule drug developed by Hospital Regional de São José - Dr. Homero de Miranda Gomes. It is currently FDA-approved for Neovascular (wet) age-related macular degeneration, Diabetic macular edema, Retinal vein occlusion (branch and central).
Ranibizumab is a monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A (VEGF-A), reducing abnormal blood vessel growth and leakage in the eye.
Ranibizumab is a monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A (VEGF-A), reducing abnormal blood vessel growth and leakage in the eye. Used for Neovascular (wet) age-related macular degeneration, Diabetic macular edema, Retinal vein occlusion (branch and central).
At a glance
| Generic name | intravitreal ranibizumab injections |
|---|---|
| Sponsor | Hospital Regional de São José - Dr. Homero de Miranda Gomes |
| Drug class | VEGF inhibitor (monoclonal antibody fragment) |
| Target | VEGF-A (Vascular Endothelial Growth Factor A) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Ranibizumab blocks VEGF-A, a key signaling molecule that drives pathological neovascularization and vascular permeability in retinal diseases. By neutralizing VEGF-A, it prevents the formation of abnormal blood vessels and reduces fluid accumulation in the retina, thereby slowing or halting vision loss in conditions characterized by excessive angiogenesis.
Approved indications
- Neovascular (wet) age-related macular degeneration
- Diabetic macular edema
- Retinal vein occlusion (branch and central)
- Diabetic retinopathy
- Myopic choroidal neovascularization
Common side effects
- Conjunctival hemorrhage
- Eye pain
- Floaters
- Intraocular pressure elevation
- Endophthalmitis
- Retinal detachment
Key clinical trials
- Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia (PHASE3)
- Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema (PHASE3)
- A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS) (PHASE4)
- A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME (PHASE3)
- A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD (PHASE3)
- A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm (PHASE3)
- Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- intravitreal ranibizumab injections CI brief — competitive landscape report
- intravitreal ranibizumab injections updates RSS · CI watch RSS
- Hospital Regional de São José - Dr. Homero de Miranda Gomes portfolio CI
Frequently asked questions about intravitreal ranibizumab injections
What is intravitreal ranibizumab injections?
How does intravitreal ranibizumab injections work?
What is intravitreal ranibizumab injections used for?
Who makes intravitreal ranibizumab injections?
What drug class is intravitreal ranibizumab injections in?
What development phase is intravitreal ranibizumab injections in?
What are the side effects of intravitreal ranibizumab injections?
What does intravitreal ranibizumab injections target?
Related
- Drug class: All VEGF inhibitor (monoclonal antibody fragment) drugs
- Target: All drugs targeting VEGF-A (Vascular Endothelial Growth Factor A)
- Manufacturer: Hospital Regional de São José - Dr. Homero de Miranda Gomes — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Neovascular (wet) age-related macular degeneration
- Indication: Drugs for Diabetic macular edema
- Indication: Drugs for Retinal vein occlusion (branch and central)
- Compare: intravitreal ranibizumab injections vs similar drugs
- Pricing: intravitreal ranibizumab injections cost, discount & access